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Chronic Obstructive Pulmonary Disease
History
Chronic obstructive pulmonary disease (COPD) has certainly long 
existed, but first reports that may be traced to this disease only dates 
from the seventeenth century. It was in 1679 that took place the first 
hypothetical report of COPD cases when Bonet described emphysema 
as a condition of “voluminous lungs” [1]. Almost a century ahead, 
Giovanni Morgagni described 19 cases of “turbid” lungs in 1769 
and 20 years later an emphysematous lung is illustrated by Matthew 
Baillie [1]. Early reports of chronic bronchitis were generated in 1814 
by Badham who used the word catarrh to refer to the chronic cough 
and mucus hypersecretion that are key symptoms. He also described 
bronchiolitis and chronic bronchitis as disabling disorders [1]. The 
emphysema component of disease was beautifully described by 
Laënnec (1821) in his Treatise of diseases of the chest. He recognized 
that emphysema lungs were hyperinflated and did not empty well [1]. 
Spirometer was invented in 1846 by John Hutchinson [1]. This device 
is today absolutely necessary to the correct diagnosis and management 
of COPD. However, Hutchinson’s instrument only measured vital 
capacity. A century went by until Tiffeneau was able to add the concept 
of timed vital capacity as a measure of airflow [2]. Gaensler introduced 
the concept of the air velocity index based on Tiffeneau’s work and 
later the forced vital capacity [3], which is the foundation of the FEV1 
and FEV1/FVC percent and spirometry became complete as a COPD 
diagnostic instrument. What was once called chronic obstructive 
bronchopulmonary disease, chronic airflow obstruction, chronic 
obstructive lung disease, nonspecific chronic pulmonary disease, and 
diffuse obstructive pulmonary syndrome, was coined COPD in 1965 
by William Briscoe [4].
Definition and prevalence
COPD is characterized by chronic airflow limitation that is not 
fully reversible even under bronchodilators effect, caused by a mixture 
of small airway disease - obstructive bronchiolitis - and parenchymal 
destruction - emphysema. Indeed, main components of COPD are 
chronic bronchitis and emphysema. Chronic bronchitis is defined 
by the presence of chronic recurrent increase in bronchial secretions 
sufficient to cause expectoration. These secretions must be present 
in most days for a minimum of three months per year for at least 
two consecutive years and cannot be attributed to other disorders 
[5]. Noteworthy, not every patient with chronic bronchitis has or 
will develop chronic airflow limitation [6]. Emphysema is defined 
anatomically by permanent, destructive enlargement of airspaces distal 
to the terminal bronchioles without obvious fibrosis [5].
Associated chronic inflammation causes changes and narrowing 
of the small airways leading to airway remodeling. Parenchyma 
destruction is responsible for the loss of alveolar attachments and 
decrease of lung elastic recoil [7]. These changes reduce the ability 
of the airways to remain open during expiration. No currently 
available treatments reduce the progression of COPD or suppress the 
inflammation in small airways and lung parenchyma [8]. According to 
the Global initiative for chronic Obstructive Lung Disease (GOLD)’s 
last report, COPD is defined as a preventable and treatable disease with 
some significant extrapulmonary effects that may contribute to the 
severity in individual patients [9].
*Corresponding author: Deborah Penque, Ph.D., Laboratório de Proteómica, 
Departamento de Genética, Edifício INSA II, Instituto Nacional de Saúde Dr. Ricardo 
Jorge, INSA, I.P., Avenida Padre Cruz, 1649-016 Lisboa, Portugal, Tel: +351 21750 
8137; Fax: +351 21752 6410; E-mail: deborah.penque@insa.min-saude.pt
Received December 24, 2011; Accepted February 22, 2012; Published February 
27, 2012
Citation: Alexandre BM,Penque D (2012) Chronic Obstructive Pulmonary Disease 
and Proteomics: A Match for Success? J Aller Ther S7:003. doi:10.4172/2155-
6121.S7-003
Copyright: © 2012 Alexandre BM, et al. This is an open-access article distributed 
under the terms of the Creative Commons Attribution License, which permits 
unrestricted use, distribution, and reproduction in any medium, provided the 
original author and source are credited.
Abstract
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation that is not fully 
reversible even under bronchodilators effect, caused by a mixture of small airway disease and parenchymal 
destruction. COPD is a major cause of morbidity and mortality in adults, and it is now the fourth leading death 
cause in the world. Cigarette smoking is the main risk factor for COPD but not all smokers will suffer from COPD, 
suggesting that genetic and other environmental factors are involved in this pathology. 
Current diagnosis is based on spirometry, but there is recurrent debate on fixed spirometric thresholds in use that 
lead to misdiagnosis and/or classification of COPD. The available treatments are not effective to reduce or suppress 
the progression of COPD. Hence, there is an urgent need to better understand the molecular mechanisms of COPD 
pathogenesis to provide clinicians with reliable diagnosis and treatment tools for COPD. Proteomics, defined by the 
comprehensive study of the proteome, has the potential to respond to this need by providing protein profiles of a 
particular disease and, at the same time, by identifying specific biomarkers that can be used to better understand, 
diagnose and manage the disease. Here, we shortly review COPD history and pathology and how proteomics can 
match COPD for success.
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COPD is a major cause of morbidity and mortality in adults, and its 
incidence has been increasing worldwide. In 2000, approximately 2.7 
million deaths were caused by COPD [10]. At the present time, COPD 
is the fourth leading cause of death and its prevalence and mortality are 
expected to continue increasing in next decade [9-11]. Additionally, 
COPD is the only major cause of death that is increasing in prevalence 
worldwide [12], while other causes have been declining since 1970 
[13]. Not only mortality but also morbidity associated with COPD are 
often underestimated by healthcare providers and patients as COPD is 
frequently underdiagnosed and undertreated [14].
In the US, an estimated 12 million individuals, about 4% of the 
population, were identified with COPD in 2007 [15]. Moreover, 
another 12 million were estimated to suffer from COPD undiagnosed 
[15]. In the EU, a 2009 report from the European Federation of Allergy 
and Airways Diseases Patients Associations revealed that prevalence 
varies from an estimated 2% (The Netherlands) to more than 10% 
(Austria and Germany) [16].
Diagnosis and classification
The diagnosis of COPD is based on spirometry associated with 
medical history data, such as smoking, occupational exposure and 
infection risk factors. The use of postbronchodilator spirometry is 
recommended to minimize variability [9]. According to the GOLD 
guidelines, COPD is diagnosed when there is lung obstruction, i.e., when 
forced expiratory volume in one second to forced vital capacity ratio 
(FEV1/FVC) is lower than 0.70. COPD severity stage classification is 
based on FEV1 values (Table 1). However, fixed spirometric thresholds 
to diagnosis and stage COPD remain under recurrent medical debates 
[17-20]. Since FEV1/FVC ratio declines with increasing age, a fixed 
cut-off of 0.70 leads to overdiagnosis of elder patients underdiagnosis 
among young adults [21,22]. Therefore, new surrogate biomarkers are 
of great need so that clinicians involved in primary and secondary care 
are able to attain successful early diagnosis, prognosis and monitoring 
therapeutic intervention in COPD.
Risk factors
Cigarette smoke is the most commonly encountered risk factor for 
COPD. Cigarette smoking is the leading cause of preventable death 
worldwide and yet, despite anti-smoking campaign efforts from such 
organizations as the European Respiratory Society [12], American 
Thoracic Society [23] or the World Health Organization (WHO) [24], 
the number of smokers keeps increasing. Thus, global epidemic of 
tobacco-associated diseases has progressively worsened.
Cigarette smokers have a higher prevalence of respiratory 
symptoms, lung function abnormalities, a greater rate of decline in 
forced expiratory volume in the first second, FEV1, and higher death 
rates for COPD than nonsmokers [9,12]. A 25-year follow up study of 
the general population concluded that 92% of COPD deaths occurred 
in subjects who were current smokers at the beginning of the follow 
up period and that after 25 years of smoking, at least 25% of smokers 
without initial disease will develop clinically significant and 30-40% 
will have COPD [25]. The fact that not all smokers develop clinically 
significant COPD, suggests that genetic factors may modify each 
individual risk [12].
COPD is a polygenic disease and a classical example of gene-
environment interaction [9]. The only proven genetic risk factor for 
COPD is the hereditary deficiency of α1-antitrypsin, a major circulating 
inhibitor of serine proteases, in which a smoker will considerably 
increase the risk for COPD [26]. Gene mutations and polymorphisms 
have been studied and several candidate genes associated with 
COPD phenotypes have been reported, but so far none has been 
validated [27-30]. Occupational dust, outdoor and indoor pollution, 
socioeconomic status and genetic determinants are also associated with 
the development of COPD [12].
Pathology, pathogenesis, pathophysiology and economic 
burden
Cigarette smoke and other noxious particles cause amplified 
lung inflammation in patients that develop COPD. This may induce 
parenchymal tissue destruction (emphysema) and disturb normal 
repair and defense mechanisms resulting in small airway inflammation 
[31,32]. Emphysema and small airway inflammation and damage lead 
to the enlargement of alveolar air spaces, airway wall fibrosis, loss of 
elastic recoil, smooth muscle hypertrophy, goblet cell hyperplasia 
and mucus plugging. Inflammatory exudates accumulate in the small 
airways lumen due to reduced mucociliary escalator function [31]. 
The physiological consequences are airway collapse over expiration 
leading to airflow obstruction and hyperinflation (air trapping) 
which ultimately results in characteristic symptom of breathless and 
progressive airflow limitation that may lead to death. In general, 
inflammatory and structural changes in the airways increase with 
disease severity and persist on smoking cessation [33-35].
COPD is characterized by a specific pattern of inflammation which 
involves neutrophils, macrophages and lymphocytes [7]. These cells 
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Figure 1: Pathogenesis of COPD. Source: Barnes PJ. Adapted from www.
goldcopd.org.
Disease stage Main characteristics
1: Mild COPD FEV1/FVC < 70%
FEV1 ≥ 80% predicted
With or without symptoms
2: Moderate 
COPD
FEV1/FVC < 70%
50% ≤ FEV1 < 80% predicted
With or without symptoms
3: Severe 
COPD
FEV1/FVC < 70%
30% ≤ FEV1 < 50% predicted
With or without symptoms
4: Very severe 
COPD
FEV1/FVC < 70%
FEV1 < 30% predicted or < 50% predicted plus presence of 
chronic respiratory failure (PaO2 < 60 mm Hg while breathing 
room air at sea level)
Table 1: Classification of COPD stages based on spirometry [9]. FEV1 = Forced 
Expiratory Volume in 1 sec; FVC = Forced Vital Capacity; PaO2 = Arterial Partial 
Pressure of Oxygen.
Citation: Alexandre BM,Penque D (2012) Chronic Obstructive Pulmonary Disease and Proteomics: A Match for Success? J Aller Ther S7:003. 
doi:10.4172/2155-6121.S7-003
Page 3 of 6
ISSN:2155-6121  JAT, an open access journalJ Aller Ther Pulmonary developmental biology
release inflammatory mediators and interact with structural cells in 
airways and lung parenchyma.
The wide variety of inflammatory mediators that have been 
shown to be increased in COPD patients [36] attract inflammatory 
cells from circulation amplifying the inflammatory process and 
inducing structural changes that may lead to emphysema and mucus 
hypersecretion [37].
Lung inflammation is believed to be further augmented by oxidative 
stress and an excess of proteinases in the lung. These two mechanisms 
are key players in COPD pathology (Figure 1).
It has long been proposed that several proteases disrupt connective 
tissue components, as elastin, in lung parenchyma to produce 
emphysema and that there is an imbalance in COPD patients between 
proteases and endogenous antiproteases which should protect the 
lung against protease-derived effects. In COPD, the exogenously 
and endogenously derived oxidants have been found to inactivate 
antiproteinases such as α1-antitrypsin [38]. Evidences of elastin 
degradation in COPD have been demonstrated and although early 
attention was directed to neutrophil elastase, many other proteases 
have been reported to be able to degrade elastin [7].
Oxidants are generated endogenously and exogenously, with 
cigarette smoke being heavily implicated in the latter as it contains 
many oxygen free radicals [31]. Under normal circumstances and 
despite permanent exposure to high oxygen levels, the lung is able to 
manage oxidant species by neutralizing them with several antioxidant 
mechanisms in the human respiratory tract [7,31,39]. Oxidative stress 
occurs when reactive oxygen species (ROS) are produced in excess of 
the antioxidant defense mechanisms resulting in harmful effects such 
as damage to lipids, proteins and deoxyribonucleic acid (DNA) [7,40]. 
Inflammatory and structural cells that are activated in the airways of 
COPD patients produce ROS, including neutrophils, eosinophils, 
macrophages and epithelial cells [7,40,41]. Alveolar macrophages 
are activated by free radicals and react by producing high levels 
of mediators, some of which are chemotactic for neutrophils and 
macrophages, as well as ROS and also reactive nitrogen species (RNS), 
with resultant local and systemic inflammation [31].
It is increasingly recognized that the inflammatory response 
associated with COPD extend beyond the lung [42]. Evidence of 
systemic inflammation includes activated circulating inflammatory 
cells and elevated levels of both inflammatory cytokines and acute 
phase proteins as C-reactive protein, fibrinogen, leukocytes and tumor 
necrosis factor (TNF-α) in COPD patients when compared to healthy 
subjects [43].
The origin of systemic inflammation in COPD is still unclear and 
requires further investigation, but it is likely to be a consequence of 
a number of factors, including individual susceptibility and the direct 
effects of hypoxia and noxious substances as the one of cigarette smoke 
on the peripheral vasculature and circulating inflammatory cells [31]. 
Alternatively, the observed inflammation may be a consequence of 
‘overspill’ from the lung to the peripheral circulation [31]. Systemic 
inflammation is directly linked to a number of complications commonly 
encountered in COPD patients including, but not limited to, cachexia, 
skeletal muscle dysfunction, depression, osteoporosis, diabetes/glucose 
intolerance, autoimmune disorders and cardiovascular diseases [31,42].
Among respiratory diseases, COPD is the leading cause of lost 
work days. In the United States of America, medical costs credited to 
COPD were estimated at $32.1 billion [44]. In the European Union, 
productivity losses are estimated to amount to a total of €28.5 billion 
annually [12]. Economic burden is likely to be underestimated since, for 
example, the economic value of the care provided by family members 
is not generally acknowledged. Long-term home care provided by 
relatives for COPD patients has a negative impact on professional 
careers for both patients and their family members [5]. Hence, COPD 
represents a very important threat to global economies and the 
development of new diagnostic/prognostic methodologies capable of 
providing exact medical information to the doctor in a timely manner 
is crucial to diminish the economic impact of COPD worldwide.
Proteomics
Definition
The Proteome is, by definition, the total set of proteins expressed 
by a given cell, tissue, organ or organism at a certain time under certain 
defined conditions [45]. Proteomics is defined by the large-scale study 
of the proteome. The human genome has been sequenced a decade ago 
and about 20,000 genes were accounted. Genome sequencing contains 
valuable information to proteomics. Proteomics has the ability to 
raise our knowledge to a higher level providing new insights into the 
pathophysiology of many diseases ultimately leading to new prognosis 
and diagnosis, and also to novel therapeutical treatments.
Background and state-of-the-art
The advent of proteomics has brought with it the hope of 
discovering novel biomarkers that can be used to diagnose a specific 
disease, predict susceptibility and monitor disease progression and 
treatment responses, among many other applications. This hope is built 
on the ability of proteomic technologies, such as mass spectrometry 
(MS), to identify hundreds of proteins in complex biofluids such as 
plasma and serum. Very few if any analytical instruments surpass the 
mass spectrometer in the versatility of its application in both basic and 
applied research, as it is the case of biomarker discovery. To support 
this statement, it is sufficient to mention that mass spectrometry can be 
used for applications ranging from characterization of electronic excited 
states and vibrational levels of simple molecules to the construction of 
protein interaction maps in multicellular organisms. This is also the 
result of almost one hundred years of mass spectrometry utilization 
since Sir J. J. Thomson was able to create the first mass spectrometer 
in 1913 [46]. For over 80 years ionization methods had excluded 
the study of large molecules, including peptides and proteins. In the 
1980s, this paradigm changed with the introduction of new ionization 
methods as electrospray ionization (ESI) [47] and matrix-assisted laser 
desorption ionization (MALDI) [48,49]. These simple and sensitive 
ionization methods have been coupled to different types of analyzers 
such as triple quadrupoles, three-dimensional ion traps, and time of 
flight (TOF) , including its orthogonal version which allowed coupling 
of TOF to both pulsed (MALDI) and continuous (ESI) ionization 
types [45]. A further impetus was given to the process of ion analysis 
through the commercialization of hybrid configurations that have 
been intensively used in proteomics including, but not limited to, 
TOF-TOF, ion trap-Fourier transform (FT)-ion cyclotron resonance 
(ICR), and quadrupole-TOF. These combinations have a direct impact 
on sensitivity and resolution of the sequence information that can 
be obtained when performing tandem MS analysis [45]. At the same 
time MS was evolving, there were many advances in other fields that 
were crucial to the development of proteomics as sample preparation 
techniques and bioinformatics tools. One of the most widely used 
separation procedures is two-dimensional gel electrophoresis (2DE) 
which consists in the separation of a complex protein mixture 
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according to physicochemical properties of proteins. First, proteins are 
separated in one dimension according to their isolectric point through 
isoelectric focusing (IEF) in immobilized pH gradient (IPG) strips, and 
then separated over a second dimension according to their molecular 
weight in a sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE). This separation method was described as it is used today 
in 1975 by O’Farrell [50]. SDS-PAGE is one of many achievements that 
took place in the last 50 years and that established proteomics in the 
first line of clinical research at the present time [51].
In last decade, the shotgun proteomics approach has become the 
method of choice for identifying and quantifying proteins in most 
large-scale studies [52-55]. Compared with 2DE, shotgun proteomics 
allows higher data throughput and better protein detection sensitivity. 
This strategy is based on digesting proteins (usually with trypsin) into 
peptides. This produces a complex peptide mixture that is then separated 
by one- or multiple dimensional liquid chromatographies (LC) and 
subjected to peptide sequencing using tandem mass spectrometry (MS/
MS) before automated database searching. This strategy is compatible 
with the use of labeled samples for quantitative purposes such as stable 
isotope labeling by amino acids in cell culture (SILAC) [56], isotope 
coded affinity tags (ICAT) [57], isobaric tags for relative and absolute 
quantitation (iTRAQ™) [58] or by O16/O18 exchange [59].
The chance of combining different techniques along sample 
preparation steps with different separation methods and different 
types of mass spectrometers generates multiple complementary 
approaches whose results can be combined to achieve a higher level of 
understanding (Figure 2). Proteins are the functional molecules in the 
human body and therefore by accurately assessing the proteomes of 
healthy and disease states (including information on protein differential 
expression across conditions) we will be one step closer to determine 
what changes are responsible for disease onset and progression, to 
properly determine disease stages and to be able to monitor treatment 
efficacy.
Proteomics in COPD
There is still some debate concerning the disease-specific molecular 
mechanisms of the inflammatory process and acute exacerbation of 
COPD. Potential biomarkers which are specific for COPD have not 
been fully identified and validated, even though there is a great need for 
such biomarkers [60]. Proteomic technologies allow for identification 
of protein changes caused by the disease process and recent advances, 
especially at mass spectrometry and bioinformatics levels, raise the 
chances to identify novel putative biomarkers. Proteomics application 
to clinical samples is extremely challenging as it is subjected to natural 
variation of the human proteome (genetic, environmental) and also 
to technical aspects prior to analysis as sample collection, storage, 
handling and processing procedures. In particular, COPD proteomics 
faces the huge challenge of sample collection since obtaining enough 
amounts of proper samples is dependent on factors such as ethics and 
accessibility. Biological samples commonly used in COPD include 
bronchoalveolar lavage fluid (BALF) and sputum, but exhaled breath 
(EB), nasal lavage fluid (NLF), urine, plasma and bronchial and lung 
biopsies have also been used to study the disease. 
Despite its potential to investigate the mechanisms of many 
diseases and the existence of a systemic component in COPD, the 
use of plasma had limited importance to COPD proteomics so far. A 
similar rationale can be stated for lung and bronchial biopsies. These 
samples possess enormous potential for determining the agents and 
mechanisms at the site disease and therefore to identify biomarkers 
that could then be translated into the clinic. However, the procedure to 
collect these samples is extremely invasive and collected samples often 
differ in terms of histology and protein content. Sputum is considered 
to represent bronchial lining fluid and induced sputum may in this 
way be an important source for proteomics research since it contains 
enough protein amounts to engage proteomics studies. BALF and NLF 
result from respiratory epithelial lining washing, which are relatively 
non-invasive techniques that are able to collect samples which are 
representative of the upper airways. Our group has successfully 
demonstrated that the use of nasal epithelial cells (NEC) collected by 
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Figure 2: Workflow illustrating different proteomics-based approaches and major steps required for proteomic biomarker discovery.
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nasal brushing is capable of yielding numerous and well-preserved 
dissociated cells that are representative of the human superficial 
respiratory mucosa [61] and their utility in the study of the monogenic 
disease cystic fibrosis by proteomics [62,63]. NECs were also reported 
to constitute an accessible surrogate for studying lower airway 
inflammation [64]. Importance of these cells and their application to 
respiratory proteomics have recently been reviewed [65].
Information on putative biomarkers for COPD generated from 
several proteomics studies has been gathered in recent reviews [60,66]. 
Samples collected form BALF, sputum and lung tissues were able to 
provide differentially expressed proteins in COPD. Regarding BALF, 
there were four proteins reported to be differentially expressed in 
COPD (Neutrophil defensins 1 and 2 and calgranulin A and B) [67] 
and in sputum, clara cell secretory protein (CCSP) and SP-A were the 
two proteins reported as potential biomarkers [68,69]. Concerning lung 
tissues, two studies mentioned in this review yielded 12 differentially 
expressed proteins when compared to healthy controls, including 
matrix metalloproteinase-13 (MMP-13) and again surfactant protein 
A (SP-A) [69,70]. 
Surprisingly, to date only 57 reports (14 are reviews) match the 
search at Pubmed (http://www.ncbi.nlm.nih.gov/pubmed, accessed 
December 20, 2011) for COPD proteomics, while proteomics and 
COPD account for about 30,000 each when separately searched. Hence, 
there is a clear need to engage clinically valuable proteomics studies in 
order to match the need for new biomarkers in COPD. Proteomics has 
proved to be an excellent tool to identify disease biomarkers in COPD 
and sample collection is indeed what needs to improve. Accurate and 
updated clinical data ranging all aspects directly and indirectly related 
to the disease is the most important step in clinical proteomics and it is 
particular important to COPD since COPD is a combination of distinct 
features, including the systemic ones. Then, the source of biospecimens 
is also of extreme importance, not its choice, but especially to what 
standard collecting procedures is concerned. This may involve 
training clinicians in biopsies collection to ensure reproducibility and 
adoption of a standard procedure for sample handling and processing 
until the results are generated. To overcome ethics and invasiveness 
issues, NECs collected by the non-invasive and painful procedure of 
nasal brushing may be the right option to study COPD by means of 
proteomics. Another important issue is that COPD shares some clinical 
features with other pulmonary diseases such as asthma or cystic fibrosis 
and therefore comparing the proteome of COPD patients with healthy 
controls may not be enough when searching for specific biomarkers for 
the disease. It is recommended to incorporate patients suffering from 
other disorders that mimic features of COPD as control groups for 
discovery of reliable specific biomarkers for COPD [71]. 
Once the aforementioned premises are fulfilled, proteomics and 
COPD will certainly be a match for success and coming years will 
confirm this statement and clinicians and their patients will greatly 
profit from this alliance.
References
1. Petty TL (2006) The history of COPD. Inter J Chron Obstruct Pulmon Dis 1: 
3-14.
2. Tiffeneau R, Pinelli (1947) Air circulant et air captif dans l’exploration de la 
fonction venti- latrice pulmonaire. Paris Med 37: 624-628.
3. Gaensler EA (1950) Air velocity index; a numerical expression of the functionally 
effective portion of ventilation. Am Rev Tuberc 62: 17-28.
4. Briscoe WA, Nash ES (1965) The Slow Space in Chronic Obstructive 
Pulmonary Diseases. Ann NY Acad Sci 121: 706-722.
5. Viegi G, Pistelli F, Sherrill DL, Maio S, Baldacci S, et al. (2007) Definition, 
epidemiology and natural history of COPD. Eur Respir J 30: 993-1013.
6. Vestbo J, Lange P (2002) Can GOLD Stage 0 provide information of prognostic 
value in chronic obstructive pulmonary disease? Am J Respir Crit Care Med 
166: 329-332.
7. Barnes PJ, Shapiro SD, Pauwels RA (2003) Chronic obstructive pulmonary 
disease: molecular and cellular mechanisms. Eur Respir J 22: 672-688.
8. Barnes PJ, Stockley RA (2005) COPD: current therapeutic interventions and 
future approaches. Eur Respir J 25: 1084-1106.
9. (2010) Global strategy for the diagnosis, management, and prevention of 
chronic obstructive pulmonary disease.
10. Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, et al. (2006) Chronic 
obstructive pulmonary disease: current burden and future projections. Eur 
Respir J 27: 397-412.
11. World health organization (2000).
12. European White Lung Book (2003).
13. Jemal A, Ward E, Hao Y, Thun M (2005) Trends in the leading causes of death 
in the United States, 1970-2002. JAMA 294: 1255-1259.
14. Pauwels RA, Rabe KF (2004) Burden and clinical features of chronic obstructive 
pulmonary disease (COPD). Lancet 364: 613-620.
15. (2009) NHLBI Morbidity & Mortality: Chart Book on Cardiovascular, Lung, and 
Blood Diseases.
16. (2009) EFA Book on Chronic Obstructive Pulmonary Disease in Europe. 
Sharing and Caring.
17. Soriano JB, Zielinski J, Price D (2009) Screening for and early detection of 
chronic obstructive pulmonary disease. Lancet 374: 721-732.
18. Celli BR, Halbert RJ (2010) Point: should we abandon FEV/FVC <0.70 to detect 
airway obstruction? No. Chest 138: 1037-1040.
19. Enright P, Brusasco V (2010) Counterpoint: should we abandon FEV/FVC < 
0.70 to detect airway obstruction? Yes. Chest 138: 1040-1042.
20. Soriano JB, Rodriguez-Roisin R (2011) Chronic obstructive pulmonary disease 
overview: epidemiology, risk factors, and clinical presentation. Proc Am Thorac 
Soc 8: 363-367.
21. Lamprecht B, Schirnhofer L, Kaiser B, Buist SA, Mannino DM, et al. (2011) 
Subjects with Discordant Airways Obstruction: Lost between Spirometric 
Definitions of COPD. Pulm Med 2011: 780215.
22. TR, Smeele IJ, Thoonen BP, Lucas AE, Grootens JG, et al. (2008) Current 
clinical guideline definitions of airflow obstruction and COPD overdiagnosis in 
primary care. Eur Respir J 32: 945-952.
23. (2010) Breathing in America: Diseases, Progress and Hope.
24. Mackay J, Eriksen M (2002) The Tobacco Atlas, World Health Organization.
25. Lokke A, Lange P, Scharling H, Fabricius P, Vestbo J (2006) Developing COPD: 
a 25 year follow up study of the general population. Thorax 61: 935-939.
26. Stoller JK, Aboussouan LS (2005) Alpha1-antitrypsin deficiency. Lancet 365: 
2225-2236.
27. Molfino NA (2007) Current thinking on genetics of chronic obstructive pulmonary 
disease. Curr Opin Pulm Med 13: 107-113.
28. Molfino NA (2004) Genetics of COPD. Chest 125: 1929-1940.
29. Molfino NA, Coyle AJ (2008) Gene-environment interactions in chronic 
obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 3: 491-497.
30. Wood AM, Stockley RA (2006) The genetics of chronic obstructive pulmonary 
disease. Respir Res 7: 130.
31. Heaney LG, Lindsay JT, McGarvey LP (2007) Inflammation in chronic 
obstructive pulmonary disease: implications for new treatment strategies. Curr 
Med Chem 14: 787-796.
32. Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, et al. (2004) The nature 
of small-airway obstruction in chronic obstructive pulmonary disease. The N 
Eng J Med 350: 2645-2653.
33. Lapperre TS, Postma DS, Gosman MM, Snoeck-Stroband JB, ten Hacken NH, 
Citation: Alexandre BM,Penque D (2012) Chronic Obstructive Pulmonary Disease and Proteomics: A Match for Success? J Aller Ther S7:003. 
doi:10.4172/2155-6121.S7-003
Page 6 of 6
ISSN:2155-6121  JAT, an open access journalJ Aller Ther Pulmonary developmental biology
et al. (2006) Relation between duration of smoking cessation and bronchial 
inflammation in COPD. Thorax 61: 115-121.
34. Lapperre TS, Sont JK, van Schadewijk A, Gosman MM, Postma DS, et al. 
(2007) Smoking cessation and bronchial epithelial remodelling in COPD: a 
cross-sectional study. Respiratory research 8: 85.
35. Roth M (2008) Pathogenesis of COPD. Part III. Inflammation in COPD. Int J 
Tuberc Lung Dis 12: 375-380.
36. Barnes PJ (2004) Mediators of chronic obstructive pulmonary disease. 
Pharmacol Rev 56: 515-548.
37. Barnes PJ (2009) The cytokine network in chronic obstructive pulmonary 
disease. Am J Respir Cell Mol Biol 41: 631-638.
38. Mak JC (2008) Pathogenesis of COPD. Part II. Oxidative-antioxidative 
imbalance. Int J Tuberc Lung Dis 12: 368-374.
39. MacNee W (2005) Pathogenesis of chronic obstructive pulmonary disease. Pro 
Am Thorc Soc 2: 258-266.
40. Rahman I, Adcock IM (2006) Oxidative stress and redox regulation of lung 
inflammation in COPD. Eur Respir J 28: 219-242.
41. MacNee W (2001) Oxidative stress and lung inflammation in airways disease. 
European journal of pharmacology 429: 195-207.
42. Agusti A, Soriano JB (2008) COPD as a systemic disease. COPD 5: 133-138.
43. Gan WQ, Man SF, Senthilselvan A, Sin DD (2004) Association between chronic 
obstructive pulmonary disease and systemic inflammation: a systematic review 
and a meta-analysis. Thorax 59: 574-580.
44. Mannino DM, Buist AS (2007) Global burden of COPD: risk factors, prevalence, 
and future trends. Lancet 370: 765-773.
45. Hamdan M, Righetti PG (2005) Proteomics today: protein assessment and 
biomarkers using mass spectrometry, 2D electrophoresis, and microarray 
technology. 
46. Thomson JJ (1913) Rays of Positive Electricity and Their Application to 
Chemical Analysis. Longman’s Green and Company, London.
47. Yamashita M, Fenn, JB (1984) Electrospray Ion Source. Another Variation on 
the Free-Jet Theme. J Phys Chem 88: 4451-4459. 
48. Karas M, Hillenkamp F (1988) Laser desorption ionization of proteins with 
molecular masses exceeding 10,000 daltons. Anal Chem 60: 2299-2301.
49. Tanaka K, Waki H, Ido Y, Akita S, Yoshida Y, et al. (1988) Protein and polymer 
analyses up to m/z 100 000 by laser ionization time-of-flight mass spectrometry. 
Rapid Communications in Mass Spectrometry 2: 151-153.
50. O’Farrell PH (1975) High resolution two-dimensional electrophoresis of 
proteins. J Bio Chem 250: 4007-4021.
51. Penque D (2009) Two-dimensional gel electrophoresis and mass spectrometry 
for biomarker discovery. PROTEOMICS - Clinical Applications 3: 155-172.
52. Washburn MP, Wolters D, Yates JR (2001) Large-scale analysis of the yeast 
proteome by multidimensional protein identification technology. Nat Biotechnol 
19: 242-247.
53. Nesvizhskii AI (2007) Protein identification by tandem mass spectrometry and 
sequence database searching Methods Mol Biol 367: 87-119.
54. Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 
422: 198-207.
55. Nilsson T, Mann M, Aebersold R, Yates JR, Bairoch A, et al. (2010) Mass 
spectrometry in high-throughput proteomics: ready for the big time. Nat 
Methods 7: 681-685.
56. Ong SE, Mann M (2007) Stable isotope labeling by amino acids in cell culture 
for quantitative proteomics. Methods Mol Biol 359: 37-52.
57. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, et al. (1999) Quantitative 
analysis of complex protein mixtures using isotope-coded affinity tags. Nat 
Biotechnol 17: 994-999.
58. Shadforth IP, Dunkley TP, Lilley KS, Bessant C (2005) i-Tracker: for quantitative 
proteomics using iTRAQ. BMC Genomics 6: 145.
59. Ye X, Luke B, Andresson T, Blonder J (2009) 18O stable isotope labeling in 
MS-based proteomics. Brief Funct Genomic Proteomic 8: 136-144.
60. Chen H, Wang D, Bai C, Wang X (2010) Proteomics-based biomarkers in 
chronic obstructive pulmonary disease. J Proteome Res 9: 2798-2808.
61. Beck S, Penque D, Garcia S, Gomes A, Farinha C, et al. (1999) Cystic fibrosis 
patients with the 3272-26A-->G mutation have mild disease, leaky alternative 
mRNA splicing, and CFTR protein at the cell membrane. Hum Mutat 14: 133-
144.
62. Gomes-Alves P, Imrie M, Gray RD, Nogueira P, Ciordia S, et al. (2009) SELDI-
TOF biomarker signatures for cystic fibrosis, asthma and chronic obstructive 
pulmonary disease. Clin Biochem 43: 168-177.
63. Roxo-Rosa M, da Costa G, Luider TM, Scholte BJ, Coelho AV, et al. (2006) 
Proteomic analysis of nasal cells from cystic fibrosis patients and non-cystic 
fibrosis control individuals: search for novel biomarkers of cystic fibrosis lung 
disease. Proteomics 6: 2314-2325.
64. McDougall CM, Blaylock MG, Douglas JG, Brooker RJ, Helms PJ, et al. (2008) 
Nasal epithelial cells as surrogates for bronchial epithelial cells in airway 
inflammation studies. Am J Respir Cell Mol Biol 39: 560-568.
65. T, Charro N, Blonder J, Faria D, Couto FM, et al. (2011) Molecular profiling of 
the human nasal epithelium: A proteomics approach. J Proteomics 75: 56-69.
66. Lin JL, Bonnichsen MH, Nogeh EU, Raftery MJ, Thomas PS (2010) Proteomics 
in detection and monitoring of asthma and smoking-related lung diseases. 
Expert Rev Proteomics 7: 361-372.
67. Merkel D, Rist W, Seither P, Weith A, Lenter MC (2005) Proteomic study of 
human bronchoalveolar lavage fluids from smokers with chronic obstructive 
pulmonary disease by combining surface-enhanced laser desorption/ionization-
mass spectrometry profiling with mass spectrometric protein identification. 
Proteomics 5: 2972-2980.
68. Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, et al. (2008) Sputum 
proteomics in inflammatory and suppurative respiratory diseases. Am J Respir 
Crit Care Med 178: 444-452.
69. Lee EJ, In KH, Kim JH, Lee SY, Shin C, et al. (2009) Proteomic analysis in lung 
tissue of smokers and COPD patients. Chest 135: 344-352.
70. Ohlmeier S, Vuolanto M, Toljamo T, Vuopala K, Salmenkivi K, et al. (2008) 
Proteomics of Human Lung Tissue Identifies Surfactant Protein A as a Marker 
of Chronic Obstructive Pulmonary Disease. J Proteome Res 7: 5125-5132.
71. Mischak H, Apweiler R, Banks RE, Conaway M, Coon J, et al. (2007) Clinical 
proteomics: A need to define the field and to begin to set adequate standards. 
Proteomics Clin Appl 1: 148-156.
Submit your next manuscript and get advantages of OMICS 
Group submissions
Unique features:
•	 User	friendly/feasible	website-translation	of	your	paper	to	50	world’s	leading	languages
•	 Audio	Version	of	published	paper
•	 Digital	articles	to	share	and	explore
Special features:
•	 200	Open	Access	Journals
•	 15,000	editorial	team
•	 21	days	rapid	review	process
•	 Quality	and	quick	editorial,	review	and	publication	processing
•	 Indexing	at	PubMed	(partial),	Scopus,	DOAJ,	EBSCO,	Index	Copernicus	and	Google	Scholar	etc
•	 Sharing	Option:	Social	Networking	Enabled
•	 Authors,	Reviewers	and	Editors	rewarded	with	online	Scientific	Credits
•	 Better	discount	for	your	subsequent	articles
Submit	your	manuscript	at:	http://www.editorialmanager.com/acrgroup/
This	article	was	originally	published	in	a	special	issue,	Pulmonary develop-
mental biology  handled	by	Editor(s).	Dr.	Rodolfo	de	Paula	Vieira,	University	
Hospital	Freiburg,	German
